Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

NCT02340780 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

NETWORK

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Buparlisib

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]